Senicapoc for early Alzheimer’s symptoms
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This Phase 2 study tests whether the drug senicapoc can slow or improve symptoms in people with early Alzheimer’s disease or mild memory impairment. You would have a 50/50 chance of getting senicapoc or a placebo (inactive pill), along with regular study visits and testing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 55 and 85 years old
- Be fluent in English or Spanish
- Have early Alzheimer’s diagnosis or mild amnestic memory impairment, confirmed by study doctors
- Have a memory/thinking test score in a specific range (MoCA) and a Clinical Dementia Rating (CDR) of 0.5 or 1
- Have a study partner who can spend at least 6 hours per week with you and answer questions with you (not judge you)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a medicine called siponimod, already used for multiple sclerosis, can help people with mild Alzheimer's dementia. You will take a pill daily and be monitored closely for safety and cognitive changes.
This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.
This trial tests whether NPC-1, a new drug, can help people with early memory changes or Alzheimer's. Your blood or PET scan will show if you have Alzheimer's-related brain changes, which is required for this study.
This Phase 2 trial tests an oral medicine (EX039) to see if it can help people with mild Alzheimer’s disease. It focuses on slowing or improving thinking and memory problems over time.
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
This Phase 1 study tests whether an existing type of anti-viral medicine (nucleoside reverse transcriptase inhibitors) can help people with early Alzheimer’s disease. It also focuses on safety and proper dosing while measuring brain-related changes and memory-related symptoms.
Hear when a new Mild Cognitive Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.